Introduction: the article represents prospective study results of the treatment dynamics among patients with chronic viral hepatitis B, infected with human immunodeficiency virus. Particularly, the role of qHBsAg dynamics in the serum concerning CHB treatment effectiveness of CHB/HIV coinfected patients as well as clinical and laboratory factors influencing on this marker. The study purpose: To assess treatment dynamics of CHB/HIV coinfected patients basing on quantitative HBsAg determination and other clinical and laboratory test applying. Material and methods: 60 coinfected patients were examinedthe main group, 60 CHB monoinfected patientscomparison group to reach established study purpose.Diagnosis of HIV and chronic hepatitis B were verified. A clinical, laboratory, serological, molecular-genetic methods were used. Statistical processing of results was held with applying parametric and nonparametric methods for the data analysis.

The prevalence and inclination to chronization of viral hepatitis B is 3-5 times higher in patients with HIV-infection than in HIV-negative ones. The natural clinical course of chronic hepatitis B (CHB) in patients with HIV has the features, connected with immune suppression and mutual influence of viruses. The quantitative determination of HBsAg allows the more precise monitoring of the natural course and the dynamics of treatment of patients with CHB but these features are little studied in patients with co-infection CHB/HIV. In the work was presented the comparative analysis of the results of quantitative determination of the serum HBsAg in 59 Patients with co-infection CHB/HIV and 60 ones with chronic hepatitis. At the study it was established, that in patients with CHB/HIV co-infection were observed the reliably higher qHBsAg levels than in HIV-negative ones both in whole and in each CHB phase that depends on the immune suppression degree and DNA level of hepatitis B virus.